Drug intelligence / Profile preview

S-444823

Development stage: Unknown
Lead developer: Shionogi
Modality: Small Molecules
Administration: Topical

Overview

S-444823 is a topical small molecule G protein-coupled receptor 119 (GPR119) agonist under development by Shionogi for the treatment of atopic dermatitis. Formulated as an ointment, it is designed to act as an epidermal agent that improves skin barrier function and addresses the underlying pathology of atopic dermatitis. By targeting GPR119, which is expressed in various skin cells including keratinocytes, the drug aims to promote epidermal differentiation and reduce inflammatory responses. It is currently being evaluated in Phase 2 clinical trials in Japan.

Targets

GPR119 (Glucose-dependent insulinotropic receptor)

Beyond the preview

Go deeper on S-444823.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-444823.

Explore the full profile